Surein Arulananda

832 total citations
28 papers, 469 citations indexed

About

Surein Arulananda is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Surein Arulananda has authored 28 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Surein Arulananda's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (7 papers) and Cancer Genomics and Diagnostics (6 papers). Surein Arulananda is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (7 papers) and Cancer Genomics and Diagnostics (6 papers). Surein Arulananda collaborates with scholars based in Australia, United States and China. Surein Arulananda's co-authors include Thomas John, Alexander Dobrovic, Hongdo Do, Paul Mitchell, Ashan Musafer, W. Douglas Fairlie, Erinna F. Lee, Jonathan Cebon, Marco Evangelista and John M. Mariadason and has published in prestigious journals such as Clinical Cancer Research, Cell Death and Disease and BMJ Open.

In The Last Decade

Surein Arulananda

22 papers receiving 467 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Surein Arulananda Australia 9 230 228 205 83 50 28 469
Jiyeon Yun South Korea 11 258 1.1× 256 1.1× 228 1.1× 95 1.1× 45 0.9× 19 500
Hidejiro Torigoe Japan 13 242 1.1× 216 0.9× 186 0.9× 108 1.3× 35 0.7× 28 450
Djamila Ouaret United Kingdom 10 278 1.2× 281 1.2× 142 0.7× 147 1.8× 35 0.7× 15 583
Miso Kim South Korea 12 181 0.8× 245 1.1× 156 0.8× 91 1.1× 127 2.5× 30 463
Hyatt Balke‐Want Germany 7 222 1.0× 323 1.4× 307 1.5× 90 1.1× 51 1.0× 14 464
Jorge D. Gallo United States 10 355 1.5× 337 1.5× 127 0.6× 75 0.9× 37 0.7× 23 558
Denis Cominetti Italy 15 314 1.4× 154 0.7× 153 0.7× 107 1.3× 26 0.5× 19 570
Gillian Bethune Canada 8 189 0.8× 222 1.0× 149 0.7× 119 1.4× 24 0.5× 18 483
Gorjan Hrustanovic United States 8 279 1.2× 167 0.7× 137 0.7× 114 1.4× 39 0.8× 8 415
Erkan Yuca United States 11 323 1.4× 188 0.8× 122 0.6× 100 1.2× 37 0.7× 21 492

Countries citing papers authored by Surein Arulananda

Since Specialization
Citations

This map shows the geographic impact of Surein Arulananda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Surein Arulananda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Surein Arulananda more than expected).

Fields of papers citing papers by Surein Arulananda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Surein Arulananda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Surein Arulananda. The network helps show where Surein Arulananda may publish in the future.

Co-authorship network of co-authors of Surein Arulananda

This figure shows the co-authorship network connecting the top 25 collaborators of Surein Arulananda. A scholar is included among the top collaborators of Surein Arulananda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Surein Arulananda. Surein Arulananda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Faltys, Martin, Marliese Alexander, Sagun Parakh, et al.. (2025). Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer. Lung Cancer. 209. 108786–108786.
2.
Kumar, Beena, et al.. (2025). ImpACT Project: Improving Access to Clinical Trials in Victoria, an Artificial Intelligence–Based Approach. JCO Clinical Cancer Informatics. 9(9). e2400137–e2400137.
3.
Balasubramanian, Akhila, Jodie Palmer, Michael Christie, et al.. (2025). Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial. Clinical Cancer Research. 31(22). 4644–4654.
4.
5.
Lee, Kathryn, et al.. (2024). Implementation of a nurse-led, multidisciplinary model of care for older adults with cancer: a process evaluation protocol. BMJ Open. 14(1). e077005–e077005. 2 indexed citations
6.
Lu, Sheng, Haichuan Hu, Yao Li, et al.. (2024). Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma based on real-world cumulative clinical data. Translational Lung Cancer Research. 13(6). 1296–1306. 3 indexed citations
7.
8.
Harvey, Christopher, Tien K. Khoo, Bailin Zhang, et al.. (2023). MA17.05 Real World Outcomes of Immunotherapy (IO) for Pleural MESOthelioma in Australia - RIOMeso. Journal of Thoracic Oncology. 18(11). S163–S163. 1 indexed citations
9.
Wang, Yang, et al.. (2022). Minimal residual disease in EGFR-mutant non-small-cell lung cancer. Frontiers in Oncology. 12. 1002714–1002714. 3 indexed citations
10.
Ren, Dunqiang, Xiaoqian Ding, Satoru Miura, et al.. (2021). Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review. Annals of Translational Medicine. 9(24). 1805–1805. 4 indexed citations
11.
Arulananda, Surein, Megan A. O’Brien, Marco Evangelista, et al.. (2021). A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discovery. 7(1). 122–122. 30 indexed citations
12.
Lickliter, Jason D., Hui Gan, Mark Voskoboynik, et al.. (2020). <p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia</p>. Drug Design Development and Therapy. Volume 14. 1177–1189. 26 indexed citations
13.
Arulananda, Surein, Megan A. O’Brien, Marco Evangelista, et al.. (2020). BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. Cell Death Discovery. 6(1). 114–114. 16 indexed citations
14.
Weickhardt, Andrew, Robert E. Kearney, Que Lam, et al.. (2020). Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. Translational Lung Cancer Research. 9(2). 360–365. 13 indexed citations
15.
Lee, Erinna F., Tiffany J. Harris, Sharon Tran, et al.. (2019). BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death and Disease. 10(5). 342–342. 142 indexed citations
16.
17.
Arulananda, Surein, Hongdo Do, Gareth Rivalland, et al.. (2019). Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. Journal of Thoracic Disease. 11(5). 1756–1764. 10 indexed citations
18.
Arulananda, Surein, Bibhusal Thapa, Marzena Walkiewicz, et al.. (2018). Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 13(10). 1588–1594. 34 indexed citations
19.
Arulananda, Surein, Hongdo Do, Ashan Musafer, et al.. (2017). Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(11). 1728–1732. 137 indexed citations
20.
Arulananda, Surein, et al.. (2011). Bronchoepidural Fistula in a Man with Actinomycosis Complicated Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(10). 1761–1762. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiyeon Yun Breakdown of academic impact, for papers by Hidejiro Torigoe Breakdown of academic impact, for papers by Djamila Ouaret Breakdown of academic impact, for papers by Miso Kim Breakdown of academic impact, for papers by Hyatt Balke‐Want Breakdown of academic impact, for papers by Jorge D. Gallo Breakdown of academic impact, for papers by Denis Cominetti Breakdown of academic impact, for papers by Gillian Bethune Breakdown of academic impact, for papers by Gorjan Hrustanovic Breakdown of academic impact, for papers by Erkan Yuca
Rankless by CCL
2026